BioHarvest Sciences Inc. Share Price

Equities

BHSC

CA09076J1084

Food Processing

Market Closed - Canadian Securities Exchange 11:30:13 26/04/2024 pm IST 5-day change 1st Jan Change
0.26 CAD +1.96% Intraday chart for BioHarvest Sciences Inc. 0.00% +20.93%

Financials

Sales 2021 2.1M 2.87M 175M Sales 2022 5.5M 7.52M 458M Capitalization 98.54M 135M 8.22B
Net income 2021 -9M -12.3M -750M Net income 2022 -11M -15.04M -917M EV / Sales 2021 77.8 x
Net cash position 2021 1.46M 1.99M 122M Net Debt 2022 8.82M 12.06M 736M EV / Sales 2022 19.5 x
P/E ratio 2021
-16.1 x
P/E ratio 2022
-8.7 x
Employees -
Yield 2021 *
-
Yield 2022
-
Free-Float 71.77%
More Fundamentals * Assessed data
Dynamic Chart
BioHarvest Sciences Inc. Announces New Campus for Botanical Synthesis CDMO and Expansion of Manufacturing Capacity CI
BioHarvest Sciences Signs First Contracts with Two Industrial Customers to Develop Complex Molecules MT
BioHarvest Sciences Inc. Announces Launch of New Contract Development and Manufacturing Organization Business Unit CI
BioHarvest Sciences Inc. Signs First Contracts with Two Industrial Customers to Develop Complex Molecules Via Its Newly Launched Botanical Synthesis CDMO Business Unit CI
BioHarvest Sciences Inc. announced that it has received CAD 13.622872 million in funding CI
Bioharvest Sciences Inc. Announces Major Product Launch of Vinia-Based Functional Coffee Products CI
BioHarvest Sciences Inc. Provides Revenue Guidance for the Fourth Quarter 2023 CI
Bioharvest Sciences Inc. Revises Revenue Guidance for the Year 2023 CI
BioHarvest Sciences Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
BioHarvest Sciences Inc. announced that it expects to receive CAD 12 million in funding CI
BioHarvest Sciences Inc. Receives Canadian Product License from Health Canada's Natural and Non-Prescription Health Products Directorate CI
BioHarvest Sciences Inc. Provides Revenue Guidance for the Third Quarter of 2023 CI
BioHarvest Sciences Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
BioHarvest Sciences Up After Reporting Closing of Private Placement of Convertible Notes MT
BioHarvest Sciences Inc. announced that it has received CAD 4.642076 million in funding CI
More news
1 day+1.96%
Current month-7.14%
1 month-5.45%
3 months+20.93%
6 months+62.50%
Current year+20.93%
More quotes
1 week
0.25
Extreme 0.25
0.26
1 month
0.24
Extreme 0.24
0.28
Current year
0.20
Extreme 0.2
0.30
1 year
0.14
Extreme 0.14
0.30
3 years
0.14
Extreme 0.14
0.54
5 years
0.10
Extreme 0.1
0.71
10 years
0.10
Extreme 0.1
0.71
More quotes
Managers TitleAgeSince
Chief Executive Officer - 09/20/09
Director of Finance/CFO 72 09/18/09
Chairman 66 27/18/27
Members of the board TitleAgeSince
Director/Board Member 57 19/13/19
Chairman 66 27/18/27
Director/Board Member 73 21/21/21
More insiders
Date Price Change Volume
26/24/26 0.26 +1.96% 21,900
25/24/25 0.255 -1.92% 19,452
24/24/24 0.26 0.00% 154,456
23/24/23 0.26 0.00% 10,500
22/24/22 0.26 0.00% 29,110

Delayed Quote Canadian Securities Exchange, April 26, 2024 at 11:30 pm IST

More quotes
BioHarvest Sciences Inc. is a Canada-based biotechnology company. The Company offers Botanical Synthesis, its patented technology process to grow plant-based molecules, without the need to grow the underlying plant. The Company is leveraging its Botanical Synthesis technology to develop the next generation of science-based and clinically proven therapeutic solutions within two major business verticals: as a contract development and production organization (CDMO) on behalf of customers seeking complex molecules, and as a creator of proprietary nutraceutical health and wellness products, which includes dietary supplements. The Company operates through two segments: Nutraceuticals and Pharmaceuticals. The Company offers a polyphenol/antioxidant superfruit product called VINIA, which is a red grape powder that supplies the benefits of red wine consumption but without the sugar, calories and alcohol found in wine.
Calendar
More about the company